Who are Intravenous Oxytocin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): insulin-like growth factor I, ACTH, continuation of oxytocin administration, Parathyroid Hormone (PTH), Adrenocorticotrophic hormone, Insulin therapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intravenous-oxytocin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Intravenous Oxytocin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intravenous Oxytocin (Intravenous Oxytocin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Peptide hormone. Area: Obstetrics and Gynecology.

phase 3 Peptide hormone Oxytocin receptor (OXTR) Obstetrics and Gynecology Small molecule Live · refreshed every 30 min

Target snapshot

Intravenous Oxytocin (Intravenous Oxytocin) — University of Wisconsin, Madison. Intravenous oxytocin is a synthetic peptide hormone that binds to oxytocin receptors to stimulate uterine contractions and promote milk letdown during lactation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Intravenous Oxytocin TARGET	Intravenous Oxytocin	University of Wisconsin, Madison	phase 3	Peptide hormone	Oxytocin receptor (OXTR)
insulin-like growth factor I	insulin-like growth factor I	Children's Hospital of Philadelphia	marketed	Growth factor; recombinant peptide hormone	IGF-1 receptor (IGF1R)
ACTH	ACTH	Providence Health & Services	marketed	Corticotropin; peptide hormone	Melanocortin-2 receptor (MC2R)
continuation of oxytocin administration	continuation of oxytocin administration	Assistance Publique - Hôpitaux de Paris	marketed	Peptide hormone / Oxytocin receptor agonist	Oxytocin receptor (OXTR)
Parathyroid Hormone (PTH)	Parathyroid Hormone (PTH)	Takeda	marketed	Peptide hormone / PTH1 receptor agonist	PTH1 receptor (PTHR1)
Adrenocorticotrophic hormone	Adrenocorticotrophic hormone	University of Ottawa	phase 3	Peptide hormone	Melanocortin-2 receptor (MC2R)
Insulin therapy	Insulin therapy	Shanghai Jiao Tong University School of Medicine	phase 3	Peptide hormone	Insulin receptor (INSR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Peptide hormone class)

Hospices Civils de Lyon · 1 drug in this class
Shanghai Jiao Tong University School of Medicine · 1 drug in this class
University of Ottawa · 1 drug in this class
University of Wisconsin, Madison · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intravenous Oxytocin — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-oxytocin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab